Travel and leisure stocks are suffering thanks to impending plans to place restrictions that could dampen December consumer spending. US stocks are on the rise as Pfizer states that their vaccine could be efficient under a three-jab regimen.
- US markets outperform as Europe loses traction
- Sterling weakens on talk of fresh Covid restrictions
- Pfizer study strengthens the case for a third jab to combat Omicron
US markets are outperforming their European counterparts, as fears over impending and ongoing restrictions dampen sentiment. While US cases are also on the rise, Joe Biden’s unwillingness to propose lockdown measures as a means to quell the spread signals less risk for stocks. The dollar strength story continues apace thanks to the view that the Fed will be given an environment which would be conducive to faster tapering and an early 2022 rate hike.
Sterling has been on the receiving end of selling pressure today, with the UK seemingly on the cusp of a fresh bout of restrictions thanks to the rapid growth Omicron cases. GBPUSD dropped into levels not seen since almost a year ago, with traders weighing up the monetary policy implications of future restrictions. Goldman Sachs has shifted their Bank of England rate expectations in response to this latest surge in Omicron, with analysts across many of the top investment banks expecting to see the MPC hold off in favour of a February rate hike. Travel and leisure stocks are also lagging behind in the UK, with recent optimism starting to wane on the prospect of greater government oversight. Nonetheless, it is important to note that while short-term measures to slow the spread of the virus may dampen economic activity over the short-term, the recent data has certainly helped allay some of the fears evident within markets last week.
A raft of early studies into the effectiveness of current vaccines have provided a somewhat inconsistent set of findings. This latest variant appears to do a good job of evading much of the protection afforded by infection or vaccines, with preliminary data showing that antibodies are 41 times less effective against this strain. However, Pfizer have provided a more positive outlook, after finding that a three-dose regimen of their vaccine has a strong neutralising effect against Omicron in the lab. With the Pharmaceutical firm planning to have a specialised Omicron jab ready for March 2022, there is plenty of reasons for shareholders to expect the bumper Covid revenues to roll through into future years.
This material is a marketing communication and shall not in any case be construed as an investment advice, investment recommendation or presentation of an investment strategy. The marketing communication is prepared without taking into consideration the individual investors personal circumstances, investment experience or current financial situation. Any information contained therein in regards to past performance or future forecasts does not constitute a reliable indicator of future performance, as circumstances may change over time. Scope Markets shall not accept any responsibility for any losses of investors due to the use and the content of the abovementioned information. Please note that forex trading and trading in other leveraged products involves a significant level of risk and is not suitable for all investors.
Recommended Content
Editors’ Picks
USD/JPY flat-lines below 151.50 after soft Japanese CPI data
USD/JPY stays defensive below 151.50 after the release of a soft Japan's CPI report and mixed Industrial Production and Retail Sales data on Friday. Japanese verbal intervention also weighs on the pair amid the holiday-thinned conditions on Good Friday. US PCE inflation awaited.
AUD/USD buyers lack vigor above 0.6500 amid Good Friday trading lull
AUD/USD is trading listlessly above 0.6500 in the Asian session amid light trading on Good Friday. The Aussie pair shrugs off encouraging comments from China's FX regulator, as price action remains subdued ahead of the US PCE inflation data.
Gold flirts with record highs above $2,230, all eyes on US PCE data
Gold price flirts with record highs around $2,230 during the Asian session on Friday. The uptick of yellow metal is bolstered by the safe-haven flows amidst growing economic concerns and the prospect of interest rate cuts from the US Federal Reserve.
Optimism price could fall as nearly $90 million worth of OP tokens is due flood markets
Optimism volatility has shrunk in the ours leading to the network’s cliff unlock. It joins the likes of dYdX and Sui, which have similar events on their calendars. As token unlocks are often considered bearish catalysts, investors should brace for a reaction after the event.
Will they won’t they cut rates is the question of Q2?
There has been some significant push back from Fed and Bank of England members around the timing of rate cuts, and the Bank of Japan still haven’t physically intervened in the FX market to stem yen weakness although they are threatening to do so.